How to balance the yield benefits of agricultural plastics with pollution risks?
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Dec-2025 12:11 ET (30-Dec-2025 17:11 GMT/UTC)
Objective
Deep venous thrombosis (DVT), a potentially life-threatening condition with a high clinical incidence, represents a significant healthcare burden in China. This study aims to investigate the prevalence of protein C (PROC) p.Lys193del mutation and promoter polymorphisms in patients with DVT in Shanghai, China.
Methods
A total of 180 patients diagnosed with DVT and 103 healthy controls underwent polymerase chain reaction amplification targeting two specific regions of the PROC gene for genetic analysis of the p.Lys193del mutation and promoter polymorphisms.
Results
The p.Lys193del mutation was significantly more prevalent in the DVT group, with 13 carriers identified (7.2%, 13/180), compared to only one carrier in the control group (0.97%, 1/103; P<0.05). Genetic analysis of PROC promoter polymorphisms revealed distinct allele distribution patterns between the groups, with significantly different frequencies for the −1654 C,−1641 G and −1476 T alleles in DVT group versus control group (P<0.05). Corresponding genotype analysis showed significant intergroup differences in the three homozygous variants: −1654C/C, −1641G/G and −1476T/T, all of which exhibited significantly higher frequencies in the DVT group compared to control group (11.1% vs. 1.9%, P<0.01).
Conclusions
The PROC p.Lys193del mutation, an established genetic risk factor for DVT, accounts for about 7.2% of DVT cases. Furthermore, three promoter polymorphisms (−1654C/C, −1641G/G, −1476T/T) were present as homozygous genotypes in 6.1% (11/180) of DVT group, demonstrating statistically significant association with thrombotic risk compared to healthy controls (P<0.05). These findings position both the p.Lys193del mutation and the promoter haplotype variants as independent genetic risk factors for venous thromboembolism in the studied population.
In a landmark move to bridge global medical innovation, LabMed Discovery has opened its first international office at the University of Rome Tor Vergata. This strategic partnership, formalized with a signing ceremony attended by Chinese and Italian delegates, promises to accelerate collaborative research and journal visibility worldwide. The office underscores China’s commitment to fostering cross-border scientific dialogue and journal excellence.
Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This manuscript provides an overview of advancements globally and in China, focusing on the classification and clinical applications of radiopharmaceuticals, particularly in oncology and neurology. Recent progress includes PET/SPECT diagnostic agents and therapeutic radionuclides that provide precise treatment while limiting damage to healthy tissues. Emerging technologies, such as artificial intelligence, novel ligands, advanced radionuclides, and combination therapies, present promising avenues to further enhance the efficacy and accessibility of the field. Despite these achievements, challenges remain in production, regulatory, and costs, underscoring the need for ongoing innovation and international collaboration to fully realize the potential of radiopharmaceuticals in personalized healthcare and optimize patient outcomes.
Long COVID continues to affect millions, with symptoms that mirror those of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This research highlight reveals that both conditions share common roots in cellular oxidative stress and immune dysfunction, potentially leading to long-term brain damage. It proposes that ME/CFS is a progressive neurodegenerative disorder and could serve as a useful model for understanding brain aging, energy failure, and the lasting neurological effects of viral pandemics.